One of the most commonly prescribed medications worldwide may have a hidden benefit.

Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors? 

Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients 

A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series. 

The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.  

The end to every day insulin use may be in sight. 

The risk for leg and foot amputation is now listed under Warnings and Precautions instead of box warning. 

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature will be a 3-part series. 

In Part 1:  Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs.  

Is a very low carbohydrate diet (VLCD) superior to an essential carbohydrate/low-fat diet (LFD) for improving body mass and insulin sensitivity? 

Have the challenges of creating an effective oral insulin finally been overcome?

Cardiovascular events decline for patients using which antidiabetic medication?

Can improving diabetes care be as simple as ensuring patients receive regular testing?